In this Science segment, we examine the European Medicines Agency’s recent decision to recommend granting marketing authorization for the anti-Alzheimer’s drug lecanemab. This follows an earlier rejection of its commercialization, citing concerns that the risks outweighed the benefits. So, what changed, and is this drug really the miracle treatment for Alzheimer’s that some claim it to be?
Trending
- Mines in the Strait of Hormuz: How dangerous are they?
- Meta to cut one in 10 jobs after spending billions on AI
- Disney+ slashes prices in surprise deal as rivalry with HBO Max heats up – but you’ll have to act fast for discount
- Waarom kinderen zich vaker moeten vervelen: ‘Goed voor de veerkracht’
- What NHS challenges does the election winner face?
- Meta lines up layoffs while Microsoft offers buyouts | Business and Economy News
- Stock markets are too high and set to fall, says Bank of England deputy
- Meta axes 8,000 jobs to fund AI spending, Microsoft to follow suit
